Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Age-Dependent Seroprevalence of JCV Antibody in Children.
Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.
Low-contrast multifocal visual evoked potentials: Identifying more shades of gray in MS.
RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate.
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Natalizumab discontinuation and disease restart in pregnancy: a case series.
A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
MSer – A new, neutral descriptor for someone with multiple sclerosis
Purkinje cell pathology and loss in multiple sclerosis cerebellum.
Secukinumab shines in small MS trial
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
Axoskeletal proteins prevent oligodendrocyte from toxic injury by upregulating survival, proliferation, and differentiation in vitro.
Biologic therapies: lessons from multiple sclerosis.
Impact of Cigarette Smoking on Conversion from Clinically Isolated Syndrome to Clinically Definite Multiple Sclerosis.
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
Dynamics of saccade parameters in multiple sclerosis patients with fatigue.
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
Heat shock protein 27 in multiple sclerosis relapses.
Pages
« first
‹ previous
…
161
162
163
164
165
166
167
168
169
…
next ›
last »